FENNEC PHARMACEUTICALS INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
FENNEC PHARMACEUTICALS INC. (FENC) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $1.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $1.71M.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $990.00K, a 24.06% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $798.00K.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2016-09-30 was $41.00K, a 355.56% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $7.03M, a 38.96% increase from fiscal 2024.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $5.06M, a 5.47% decline from fiscal 2023.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $5.35M.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2015 was $97.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.71M 10-Q · filed 2026-08-13 | $2.70M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $990.00K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $7.03M 10-K · filed 2026-03-27 | |||
| 2025-03-31 | $798.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $5.06M 10-K · filed 2026-03-27 | |||
| 2023-12-31 | $5.35M 10-K · filed 2025-03-26 | |||
| 2016-09-30 | $41.00K 10-Q · filed 2016-11-14 | $152.00K derived: sum of 2 quarters · filed 2016-11-14 | ||
| 2016-06-30 | $111.00K 10-Q · filed 2016-11-14 | |||
| 2015-12-31 | $69.00K 10-Q · filed 2016-11-14 | $78.00K derived: sum of 2 quarters · filed 2016-11-14 | $88.00K derived: sum of 3 quarters · filed 2016-11-14 | $97.00K 10-K · filed 2017-03-29 |
| 2015-09-30 | $9.00K 10-Q · filed 2016-11-14 | $19.00K derived: sum of 2 quarters · filed 2016-11-14 | $28.00K derived: sum of 3 quarters · filed 2016-11-14 | |
| 2015-06-30 | $10.00K 10-Q · filed 2016-11-14 | $19.00K derived: sum of 2 quarters · filed 2016-11-14 | ||
| 2015-03-31 | $9.00K 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |